ECSP20016283A - METHODS TO TREAT AND / OR PREVENT GRAFT DISEASE IN FRONT OF THE HOST AND / OR ALVEOLAR HEMORRHAGE AND / OR VENO-OCLUSIVE DISEASE ASSOCIATED WITH TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS - Google Patents

METHODS TO TREAT AND / OR PREVENT GRAFT DISEASE IN FRONT OF THE HOST AND / OR ALVEOLAR HEMORRHAGE AND / OR VENO-OCLUSIVE DISEASE ASSOCIATED WITH TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS

Info

Publication number
ECSP20016283A
ECSP20016283A ECSENADI202016283A ECDI202016283A ECSP20016283A EC SP20016283 A ECSP20016283 A EC SP20016283A EC SENADI202016283 A ECSENADI202016283 A EC SENADI202016283A EC DI202016283 A ECDI202016283 A EC DI202016283A EC SP20016283 A ECSP20016283 A EC SP20016283A
Authority
EC
Ecuador
Prior art keywords
disease
veno
stem cells
hematopoietic stem
methods
Prior art date
Application number
ECSENADI202016283A
Other languages
Spanish (es)
Inventor
Hans-Wilhelm Schwaeble
Gregory A Demopulos
Thomas Dudler
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of ECSP20016283A publication Critical patent/ECSP20016283A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En un aspecto, la invención proporciona métodos para inhibir los efectos de la activación del complemento dependiente de MASP-2 en un sujeto humano que padece enfermedad de injerto contra hospedador y/o hemorragia alveolar difusa y/o enfermedad veno-oclusiva asociada a un trasplante de células madre hematopoyéticas. Los métodos comprenden la etapa de administrar, a un sujeto que lo necesite, una cantidad de un agente inhibidor de MASP-2 eficaz para inhibir la activación del complemento dependiente de MASP-2.In one aspect, the invention provides methods for inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and / or diffuse alveolar hemorrhage and / or transplant-associated veno-occlusive disease. of hematopoietic stem cells. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

ECSENADI202016283A 2017-08-15 2020-03-05 METHODS TO TREAT AND / OR PREVENT GRAFT DISEASE IN FRONT OF THE HOST AND / OR ALVEOLAR HEMORRHAGE AND / OR VENO-OCLUSIVE DISEASE ASSOCIATED WITH TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS ECSP20016283A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762545864P 2017-08-15 2017-08-15

Publications (1)

Publication Number Publication Date
ECSP20016283A true ECSP20016283A (en) 2020-04-22

Family

ID=71783773

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202016283A ECSP20016283A (en) 2017-08-15 2020-03-05 METHODS TO TREAT AND / OR PREVENT GRAFT DISEASE IN FRONT OF THE HOST AND / OR ALVEOLAR HEMORRHAGE AND / OR VENO-OCLUSIVE DISEASE ASSOCIATED WITH TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS

Country Status (1)

Country Link
EC (1) ECSP20016283A (en)

Similar Documents

Publication Publication Date Title
CL2020000384A1 (en) Methods for treating and / or preventing graft versus host disease and / or diffuse alveolar hemorrhage and / or veno-occlusive disease associated with hematopoietic stem cell transplantation.
CL2017000080A1 (en) Methods to treat cancer with tigit inhibitors and anticancer agents
BR112018009311A2 (en) A method for treating a human subject suffering from persistent TMA associated with hematopoietic stem cell transplantation.
CO2017011197A2 (en) Combination therapy fgfr / pd-1 for cancer treatment
CO2018003168A2 (en) Kras expression modulators
CL2019000935A1 (en) Pharmaceutical composition, methods for treatment and uses thereof.
PE20180260A1 (en) METHODS AND KITS TO TREAT DEPRESSION
MX2017015574A (en) Inhibitors of bruton's tyrosine kinase.
UY38160A (en) IMPLANTABLE PARTICLES AND RELATED METHODS
AR101312A1 (en) COMBINATIONS OF BET INHIBITORS AND INHIBITORS OF TIROSINA QUINASA DE BRUTON
EA201591543A1 (en) COMBINED THERAPIES FOR CANCER TREATMENT WITH THE APPLICATION OF EGFR-TKI MICRORNA AND INHIBITORS
CO2021004141A2 (en) Modulators of pnpla3 expression
MX2019003134A (en) Combination therapy.
MX2019013862A (en) Combination therapy.
MX2020011817A (en) Methods for treating lymphoma.
CO2019004814A2 (en) Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease
CL2019002574A1 (en) Modulators of pcsk9 expression.
ECSP20016283A (en) METHODS TO TREAT AND / OR PREVENT GRAFT DISEASE IN FRONT OF THE HOST AND / OR ALVEOLAR HEMORRHAGE AND / OR VENO-OCLUSIVE DISEASE ASSOCIATED WITH TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS
EA202090504A1 (en) METHODS FOR TREATING AND / OR PREVENTING REACTIONS OF TRANSPLANTS AGAINST THE OWNER, AND / OR DIFFUSION ALVEOLAR BLEEDING, AND / OR VENO-OCCLUSION DISEASE CONNECTED WITH A TRANSCHEME
AR110764A1 (en) COMPOSITIONS AND METHODS FOR THE EXHAUSTION OF CD137 + CELLS
AR113874A1 (en) EZH2 INHIBITOR COMBINATION THERAPIES
EA201991135A1 (en) COMBINED THERAPY BY ARGINASE INHIBITORS